Antipsychotic-induced weight gain: a review of the literature.
By D. B. Allison, D. Casey. Journal of Clinical Psychiatry, 2001
665 citations recorded by the source corpus.
View Paper: https://www.semanticscholar.org/paper/377237fee3eeadc69a0fae33e5b53c9e8d83ad98
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- John J. McGrath
- S. Saha
- D. Chant
- C. Apovian
- J. Welham
- D. Ryan
- L. Pogach
- M. Murad
Citations in the corpus
- Pharmacological management of obesity: an endocrine Society clinical practice guideline. (2015, background): “This weight gain is of clinical concern because it impedes patient compliance and has deleterious health consequences (104, 105) in patients who are often overweight or obese to begin with.”
- Ten Putative Contributors to the Obesity Epidemic (2009, unknown): “This weight gain is of clinical concern because it impedes patient compliance and has deleterious health consequences (Allison and Casey, 2001; Kurzthaler and Fleischhacker, 2001).”
- Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. (2003, unknown): “Whole body Headache 28 (27) 28 (28) 35 (35) 31 (31) Asthenia 5 (5) 8 (8) 8 (8) 6 (6) Pain 4 (4) 6 (6) 6 (6) 2 (2) Pain, extremity 6 (6) 5 (5) 6 (6) 5 (5) Infection 4 (4) 3 (3) 5 (5) 2 (2) Pain, back 7 (7) 4 (4) 1 (1) 7 (7) Accidental injury 7 (7) 5 (5) 0 0 Cardiovascular system Tachycardia 1 (1) 4 (”
- Schizophrenia: a concise overview of incidence, prevalence, and mortality. (2008, background): “Thus, in the absence of assertive management and treatment of these side effects, it is feasible that second-generation antipsychotics could contribute to even higher SMRs in the next few decades (51, 52).”
- A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? (2007, background): “to 3-fold increase in cardiovascular mortality and a 2-fold increase in all-cause mortality,(84) these adverse effects would be expected to contribute to even higher SMRs in the next few decades.(85,86) Unfortunately, we are unable to explore the role of atypical medications as a contributing factor”
- Physical health monitoring of patients with schizophrenia. (2004, background): “A meta-analysis by Allison and Casey (7) provided an estimate of mean weight gain in patients who received standard doses of antipsychotics over a 10-week period.”